The Hindu Huddle 2025: ‘Ozempic will not solve India's obesity problem'
These drugs weren't new drugs, he explained and had been around for nearly two decades. However earlier versions of these drugs had limited 'weight-loss' benefits. Some of these drugs were effective at aiding weight-loss upto 20% but were still only suitable for a limted segment of people who were 'terribly obese' and resistant to diet and exercise-based regimen, cautioned Dr Misra, an acclaimed diabetologist with decades of research experience under his belt.
At the panel convened to discuss the challenges from non-communicable diseases in India, labelled as the 'Trojan Horse' of India healthcare, the discussants – Dr Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals; Dr Chandrakant Lahariya, Health and Social Sector Policy Adviser and Dr Misra – agreed that sedentary lifestyles, excessive consumption of high-fat and sweetened foods were they causes of this Trojan Horse incursion.
The prevalence of obesity was rising among youngsters and there was concern that were these trends to continue, the much-vaunted 'demographic dividend,' or the surplus of youth, who would power India's economic future, would become a liability, said Dr Reddy. 'We want to keep people out of hospital beds,' she underlined.
Governments and public health bodies could play a role in discouraging the 'two whites'- salt and sugar – whose excessive consumption was a problem but Dr Lahariya cautioned that sugar was a source of 'inexpensive calories' for a vast number of India's poor who often could not meet their daily caloric needs. Salt, he informed, was an integral part of the staple Indian diet and Indians on average consume twice the World Heath Organisation recommendations. That said, he suggested, imposing heavy taxes may not be advisable and instead there ought be better more visible warnings on detrimental health effects in packaged food.
Advising against mindlessly following health fads, Dr. Misra said that ketogenic diets' (low carbohydrate-high fat diets) ought not to be followed beyond three months. It was instead healthier to tweak regular diets to cut calories and increase protein content, he opined. 'So called gluten-free diets that cost thrice as much had no benefit. I'd always recommend low-cost diets,' Dr Misra advised. 'There is well-founded research that cutting 15kgs can in several cases reverse diabetes.'
While the challenges from diabetes were significant, Dr Lahariya said that India was also grappling a 'mental health' crisis.
The prevalence of some form of mental health challenge was around 12% (nearly almost as diabetes), and severe mental illness around 2%. 'It is high time that public health institutions evolved a systematic response.' he added.
While India was a developing country, it had managed to evolve a system of health screening that was 'comparable' to developed countries. 'It can certainly be improved and there is a range of options available that are a 10th of what it costs in the West,' reckoned Dr Reddy.
The Hindu Huddle 2025 is presented by Sami-Sabinsa Group
Co-powered by: Government of Karnataka, Government of Telangana
Associate Partners: ONGC, Presidency University, TAFE, Akshayakalpa Organic
Energy Partner : Indian Oil Corporation Limited
Realty partner: Casagrand
Knowledge partner: Amrita Vishwa Vidyapeetham
State partner: Meghalaya tourism and Haryana government
Luxury car partner: Toyota
Radio partner: Radio City
Gift partner: Anand Prakash
Broadcast partner: Times Now
Outdoor media partner: Signpost India
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
9 minutes ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'


Mint
11 minutes ago
- Mint
Eris Lifesciences betting on insulin expertise to boost its GLP-1 play
Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market. 'We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview. Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The market for weight loss drugs in India was over ₹600 crore in July 2025. Also Read: Piramal Pharma's loss narrows to Rs82 crore in June quarter Vaidyanathan explained that the insulin business involves building a patient service and care platform, which goes beyond just selling the product. '...there is active support from Eris' side at the patient's residence…given this insulin platform, we are very confident that we'll be able to make a success of GLP-1 as well, because it will ride on this platform," he said. Eris says they have a 'one of a kind" patient service model where they train patients to use insulin, while Novo has a service model as well and a wide network of physicians. GLP-1s or glucagon-like peptide-1 agonists are a class of drugs used to treat type-2 diabetes and obesity, which mimic the GLP-1 hormone produced in the gut to regulate blood sugar and appetite. Eris plans to rely on third parties for Active Pharmaceutical Ingredients (APIs), but will eventually bring regular semaglutide in-house. It will depend on third parties for the synthetic semaglutide API. Eris launched liraglutide, a GLP-1, in India last year and plans to be among the first wave of launches for generic semaglutide, which goes off patent in March 2026. It is not the only one. India's top drugmakers, including Dr Reddy's,Cipla, Sun Pharma,Zydus Lifesciences, and Natco, are gearing up to launch the generic semaglutide next year. The firm also has a pipeline of standalone insulin analogues and insulin analogues with GLP-1 combinations in preclinical and clinical trials. Insulin dominance Earlier this year, Novo Nordisk announced the rollback of pen-filled versions of its best-selling Human Mixtard insulin. While the vial versions will still be sold, this opens up a huge market for domestic players to fill in the country's ₹4,500 crore insulin market. Eris acquired the Insugen and Basalog brands fromBiocon Biologics last year as part of a larger deal to acquire its branded formulations business. It also sells Xsulin through a joint venture with MJ Biopharma. Also Read: Jashvik Capital acquires stake in pharma software firm for ₹400 crore Apart from innovators Novo Nordisk andSanofi, which dominate the Indian insulin market, Lupin, which acquired Eli Lilly's Huminsulin brand last year, is a key domestic player. 'So this whole democratisation of insulins and GLP-1s is something that is going to happen. The ball has been set rolling," said Vaidyanathan. Eris expects to see increased sales from recombinant human insulin (RHI) pen products in November and December as innovator inventory runs out. The company is also planning to in-source its insulin and GLP-1 production at a later stage. The company commenced production of insulin vials at its Bhopal facility in Q1FY26, and expects to start cartridge production by Q4FY26. 'Our strategy has always been that, once we deem that a product is big and strategically important, then we bring it in-house," said Vaidyanathan. Eris Lifesciences reported its Q1FY26 results on Tuesday, with its consolidated revenue up 7.4% year-on-year to ₹773 crore. Its Ebitda for the quarter stood at ₹277 crore, up 11% YoY with a 36% Ebitda margin. Net profit was up 41% to ₹125 crore. The drugmaker is focused on increasing profitability and paring down debt in FY26. Also Read: Sun Pharma net profit falls on US antitrust settlement, drug impairment costs 'All of this will be accompanied by a significant acceleration in the EPS (earnings per share) and the return ratios," said Vaidyanathan. Its EPS in Q1 was ₹9.2, and the company expects a 50% EPS growth in FY26. The company's net debt in Q1FY26 was ₹2,317 crore, and it aims to reduce debt to ₹1,800 crore by the end of the year.

The Hindu
2 hours ago
- The Hindu
Hospitals to face action over billing irregularities
District Medical and Health Officer (DMHO) S. Jeevan Rani has issued a stern warning to hospitals, nursing homes, diagnostic centres, and laboratories across Vizianagaram district for failing to prominently display tariff charts, as mandated under the Clinical Establishments (Registration and Regulation) Act, 2010. It has come to light that despite repeated warnings and reminders, many healthcare facilities in the district fail to display tariff details. Speaking to The Hindu on Monday, Dr Rani announced: 'Special inspection teams will be formed to conduct checks at every healthcare facility in the district. Hospitals must display the fee structure boards at the entrance and patient waiting areas. Hidden charges and lack of transparency in billing will not be tolerated.' She further added that many hospitals in Vizianagaram were hiding the fee structure and collecting excess fees without informing the patients. Additionally, patients were being forced to make payments at the cash counters where staff fail to provide proper answers. Another serious concern that Dr Rani highlighted was that many hospitals are not issuing hard copies of prescriptions and test reports to patients. Instead, doctors are sending the prescriptions directly to the in-house pharmacies, leaving patients unable to purchase medicines from elsewhere. 'Outstation patients have complained that they cannot buy medicines in their hometowns due to the absence of physical prescriptions,' Dr Rani added. However, hospital authorities claim that reports and prescriptions are being sent to the WhatsApp numbers of patients. Interestingly, when The Hindu tried to find out how poor patients who do not use smartphones can access their reports and prescriptions, none of the hospitals responded. B. Ramachandra Reddy, an attendant of a patient said: 'Sometimes, WhatsApp messages may be deleted. How can patients retrieve deleted data? Additionally, in case of an emergency when patients are referred to hospitals in Visakhapatnam and other places, it is not easy to take printouts. Hard copies are essential for maintaining lifelong medical records. ' Dr. Rani reiterated that hospitals must adopt transparent procedures in billing and treatment. It is mandatory. 'Patients with grievances can contact us and we will take action on errant hospital authorities,' she added.